Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-09-19
2010-02-23
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S121000
Reexamination Certificate
active
07666880
ABSTRACT:
The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to imidazo[1,2-a]pyridine containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with enzymes having histone deacetylase activities (HDAC).
REFERENCES:
patent: 6552065 (2003-04-01), Remiszewski et al.
patent: 2005/0054701 (2005-03-01), Wallace et al.
patent: 0266890 (1988-05-01), None
patent: WO-99 55705 (1999-11-01), None
patent: WO-99 59587 (1999-11-01), None
patent: WO-01 38322 (2001-05-01), None
patent: WO-03 066579 (2003-08-01), None
patent: WO-2004 021989 (2004-03-01), None
patent: 2004082638 (2004-09-01), None
patent: WO-2005 090358 (2005-09-01), None
Riester Daniel et al., Biochemical and biophysical research communications, (Nov. 19, 2004) vol. 324, No. 3, pp. 1116-1123.
Marks P.A. et al., “Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.” Journal of the National Cancer Institute, vol. 92, No. 15, Aug. 2, 2000, pp. 1210-1216.
Paris M. et al.: “Histone deacetylase inhibitors: From bench to clinic”, Journal of Medicinal Chemistry, vol. 51, No. 6, Mar. 27, 2008, pp. 1505-1529.
Supplementary European Search Report for Appln. No. EP 06717188 dated Sep. 15, 2005.
Wade P.A. “Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin” Hum. Mol. Genet. 10, 693-698(2001).
De Ruijter A.J.M. et al, “Histone deacetylases (HDACs): characterization of the classical HDAC family” Biochem. J., 370, 737-749 (2003).
Richon V.M. et al, “Second generation hybrid polar compounds are potent inducers of transformed cell differentiation” Proc. Natl. Acad. Sci. USA, 93: 5705-5708 (1996).
Richon V.M. et al, “A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases” Proc. Natl. Acad. Sci. USA, 95: 3003-3007 (1998).
Butler L.M. et al, “Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo”, Cancer Res. 60, 5165-5170 (2000).
Yoshida M. et al, “Potent and Specific Inhibition of Mammalian Histone Deacetylase Both in Vivo and in Vitro by Trichostatin A” J. Biol. Chem., 265, 17174 (1990).
Kijima M. et al, Trapoxin, an Antitumor Cyclic Tetrapeptide, Is an Irreversible Inhibitor of Mammalian Histone Deacetylase J. Biol. Chem., 268, 22429 (1993).
Bouchain G. et al, “Development of Potential Antitumor Agents. Synthesis and Biological Evaluation of a New Set of Sulfonamide Derivatives as Histone Deacetylase Inhibitors” J. Med. Chem., 46, 820-830 (2003).
Steffan J.S. et al, “Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration inDropsophila” Nature, 413 (6857), 739-43, Oct. 18, 2001.
Schindler et al., “Dissociation between Interleukin-1β mRNA and Protein Synthesis in Human Peripheral Blood Mononuclear Cells” J. Biol. Chem., 265 (18), 10232-10237 (1990).
Carballo et al, “Feedback Inhibition of Macrophage Tumor Necrosis Factor-α Production by Trisxelraprolin” Science 1998; 281: 1001-1005.
J. Taunton et al, “A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p” Science 1996 272: 408.
Blackburn C, et al “Parallel Synthesis of 3-Amino Imidazo [1,2-a] pyridines and pyrazines by a new three-component condensation”, Tetrahedron letters, 39(1998) 3635-3688.
Bienayme H, et al “A new Heterocyclic Multicomponent Reaction for the Combinatorial Synthesis of Fused 3-amino imidazoles” Angew. Chem. Int ed., 1998 37(16) 2234-2237.
Gueffier. A, et al “Synthesis of Imidazo [1, 2-a] pyridines as Anti-viral agents”, Med. Chem. 1998, 41, 5108-5112.
Lombardino, J, “Preparation and New Reactions of Imidazo [1, 2-a] pyridines”, J. Org. Chem, 1965, 30 2403.
Trapani, G, “Structure-Activity Relationships and effects on neuroactive steroid synthesis in a series of 2-Phenyl imidazo [1, 2-a] pyridine acetamide Pereripheral Benzodiazepine Receptor Ligands”, J. Med. Chem. 2005, 48292-305.
Drummond et al, “Clinical Development of Histone Deacelyal Inhibitors as Anti Cancer agents”, Ann. Rev. Pharmaceutical Toxicol. (2005) 45: 495.
Dinarello et al., “Proinflammatory and Anti-Inflammatory Cytokines in Rheumatoid Arthritis—A Primer for Clinicians”, 2nd Edition, Amgen Inc., 2000.
Lee Ken C.
Sun Eric T.
Wang Haishan
Connolly Bove & Lodge & Hutz LLP
Rahmani Niloofar
S*BIO Pte Ltd.
Seaman D. Margaret
LandOfFree
Imidazo[1,2-A]pyridine derivatives: preparation and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazo[1,2-A]pyridine derivatives: preparation and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazo[1,2-A]pyridine derivatives: preparation and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4187683